A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community.
J Antimicrob Chemother
; 36(1): 259-63, 1995 Jul.
Article
en En
| MEDLINE
| ID: mdl-8537277
ABSTRACT
We compared 40 patients taking lomefloxacin 400 mg once daily for 5 days in a double blind trial with 44 placebo takers with proven community acquired bacterial diarrhoea (85% due to Campylobacter spp.). Lomefloxacin eradicated Campylobacter spp. in 75% but did not alter clinical outcome. Twenty-eight per cent of the campylobacter isolates developed resistance. Thirty-three per cent developed side-effects. Lomefloxacin is not recommended for community-acquired bacterial diarrhoea when Campylobacter spp. predominate.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones Comunitarias Adquiridas
/
Quinolonas
/
Fluoroquinolonas
/
Diarrea
/
Antiinfecciosos
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
1995
Tipo del documento:
Article
País de afiliación:
Nueva Zelanda